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Liver fibrosis is a consequence of a wound-healing response 
to various types of chronic liver injury, and can ultimately lead 
to liver cirrhosis, portal venous hypertension, and the develop-
ment of hepatocellular carcinoma, morbidity, and mortality.1 
Thus, it is of paramount importance to assess the presence and 
degree of liver fibrosis in patients with chronic liver diseases 
(CLDs) for optimizing surveillance strategy, monitoring disease 
course, deciding on initiation of therapeutic interventions, mon-
itoring the therapeutic response, and predicting outcomes.2,3
Until recently, assessment of liver fibrosis has depended on 
liver biopsy (LB). However, LB is often limited by its invasive-
ness and extremely rare, but fatal complications including pro-
cedure-related mortality, high cost, low patient acceptance, re-
luctance of physicians, need for expertise, prolonged procedure 
time, interobserver/intraobserver interpretational variability, 
sampling error, and poor reproducibility.4 Accordingly, various 
biochemical surrogates for LB, such as the FibroTest, enhanced 
liver fibrosis test and Wisteria floribunda agglutinin-positive 
human Mac-2 binding protein (M2BP),5,6 as well as physical 
surrogates such as transient elastography (TE) and acoustic 
radiation force impulse elastography, have been proposed to 
noninvasively assess the fibrotic burden in patients with CLDs.2 
Most recently, advances in magnetic resonance imaging (MRI) 
have enabled assessment of the degree of liver fibrosis, irrespec-
tive of etiology.7,8
In this issue of Gut and Liver, Hennedige et al.9 compared 
the accuracy of 1.5-T-based magnetic resonance elastogra-
phy (MRE) and diffusion-weighted imaging (DWI) (DWI-free 
breathing [DWI-FB] and DWI-breath hold [DWI-BH]) to assess 
the degree of liver fibrosis in patients with chronic hepatitis B 
(CHB). The accuracy for detecting ≥F2/≥F3/F4 stage fibrosis by 
DWI-FB, DWI-BH and MRE was 0.84/0.76/0.72, 0.72/0.83/0.79 
and 0.99/0.99/0.98, respectively. Moreover, the performance of 
MRE was significantly better than that of DWI-FB and DWI-BH. 
Although the results of Hennedige et al.9 per se add further evi-
dence regarding the accuracy of MRE in assessing the degree of 
liver fibrosis and its superiority to DWI, several important issues 
require attention. 
First, the authors excluded patients in whom LB was per-
formed >6 months after MRI assessment, as well as those who 
received antiviral therapy (AVT) between their LB and MRI as-
sessment, to minimize the influence of potential changes due to 
the natural disease course or AVT. However, because interven-
ing events, such as changes in viral replication and the corre-
sponding fluctuations of alanine aminotransferase (ALT) level, 
can occur, the potential bias due to the relatively wide time 
interval between LB and MRI assessment (6 months) should be 
considered. The extremely small sample size for each fibrosis 
stage is another issue. Second, the heterogeneous indications for 
LB might have confounded the results. If patients received LB 
for follow-up with or without therapeutic interventions such as 
AVT, we can hypothesize that the patients were not indicative 
of AVT or showed appropriate viral suppression with potentially 
regressed fibrosis due to prolonged AVT. In contrast, if patients 
underwent LB to decide initiation of AVT, they might have 
a higher probability of an unstable liver status, such as high 
necroinflammation with/without intrahepatic cholestasis due 
to active viral replication requiring the initiation of AVT. All 
variables above-including prolonged AVT, fibrosis regression, 
necroinflammation, and intrahepatic cholestasis-can influence 
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the diagnostic accuracy of MRE. Indeed, the mean stiffness val-
ue of A2 necroinflammation in this study was higher than those 
of A1 and A2 (5.5 kPa vs 4.3 kPa and 4.1 kPa). Third, detailed 
clinical information, especially laboratory results, is lacking. 
Based on this information, the study population should have 
been selected more carefully to prevent the potential influence 
of well-known confounders of elastography, such as a high 
ALT level or heart failure. In addition, the correlation between 
ALT level and stiffness by MRE should have been investigated. 
Furthermore, using these clinical variables, the accuracy of MRE 
could have been compared with those of other simple nonin-
vasive parameters, such as the aspartate-to-platelet ratio index 
(APRI) or FIB-4, to support the superiority of MRE in assessing 
the degree of liver fibrosis. Lastly, because LB is an imperfect 
gold standard, an area under the receiver operating characteris-
tic curve (AUC) value of >0.90–0.95 does not necessarily mean 
that the predictive accuracy of a given surrogate is approaching 
diagnostic perfection.10 In addition, small differences in AUC do 
not necessarily mean that one noninvasive surrogate has an in-
ferior performance, because whether this difference in the AUC 
value is due to noninvasive surrogates, LB, or both is unclear. 
Therefore, the performance of noninvasive surrogates should 
be evaluated in long-term follow-up, longitudinal studies using 
solid clinical endpoints, such as the development of hepatic de-
compensation, hepatocellular carcinoma, or liver-related death.
Despite the aforementioned pitfalls, Hennedige et al.9 con-
ducted a head-to-head comparative study of the diagnostic 
accuracy of MRE in assessing the degree of liver fibrosis in pa-
tients with CHB. Indeed, it has been reported that MRE has the 
highest accuracy among several other surrogates (AUC>0.90) for 
assessing fibrotic burden in patients with CLDs.7 However, few 
confirmatory studies have been performed compared to other 
surrogates, such as TE. Although the accuracy of MRE has been 
confirmed and it has many advantages-such as high specificity 
for the liver, estimation of the entire liver, being unaffected by 
obesity, simultaneous assessment of liver and tumor informa-
tion, simultaneous magnetic resonance spectroscopic evaluation 
of steatotic burden-the application of MRE for noninvasive 
assessment of liver fibrosis cannot be expanded until unmet is-
sues, such as the high cost, nonimmediate acquisition of results, 
needs for specific equipment (mostly available at tertiary aca-
demic institutes), low accuracy under conditions of iron over-
load, nonapplicability to patients with implantable devices, and 
lack of standardization across platforms, especially for DWI, are 
resolved.
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